Journal
BIOLOGICAL CHEMISTRY
Volume 397, Issue 10, Pages 1005-1016Publisher
WALTER DE GRUYTER GMBH
DOI: 10.1515/hsz-2016-0166
Keywords
fibrin; p11; plasmin; proteolysis; retinopathy; tumor
Categories
Funding
- National Heart, Lung, and Blood Institute [HL042493]
- U.S. Department of Defense [MR130194]
- March of Dimes Foundation [6-FY15-356]
- Qatar National Research Fund [5-932-3-208, 6-736-3-187]
Ask authors/readers for more resources
The formation of new blood vessels from preexisting vasculature, the process known as angiogenesis, is highly regulated by pro- and anti-angiogenic signaling molecules including growth factors and proteases. As an endothelial cell-surface co-receptor for plasminogen and tissue plasminogen activator, the annexin A2 ( ANXA2) complex accelerates plasmin generation and facilitates fibrinolysis. Plasmin can subsequently activate a downstream proteolytic cascade involving multiple matrix metalloproteinases. Thus, in addition to maintaining blood vessel patency, the ANXA2 complex can also promote angiogenesis via its pro-fibrinolytic activity. The generation of ANXA2-deficient mice allowed us to first observe the pro-angiogenic role of ANXA2 in vivo. Further investigations have provided additional details regarding the mechanism for ANXA2 regulation of retinal and corneal angiogenesis. Other studies have reported that ANXA2 supports angiogenesis in specific tumor-related settings. Here, we summarize results from in vivo studies that illustrate the pro-angiogenic role of ANXA2, and discuss the critical questions that may lead to an advanced understanding of the molecular mechanisms for ANXA2-mediated angiogenesis. Finally, highlights from studies on ANXA2-interacting agents offer potential therapeutic opportunities for the application of ANXA2-centered pharmaceuticals in angiogenesis-related disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available